Taro Pharmaceutical Industries Profit Margin

Taro Pharmaceutical Industries (TARO) currently reports a profit margin of 8.56% as of March 2024. That compares with 4.44% in the prior-year period — up 92.8% year over year. That is below the Healthcare sector average of 13.89%. Use the charts on this page to explore Taro Pharmaceutical Industries's profit margin history and peer comparisons.

Taro Pharmaceutical Industries's profit margin increased from 4.44% to 8.56% — a 92.8% year-over-year increase (period ending March 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Taro Pharmaceutical Industries's profit margin of 8.56% is lower than the Healthcare sector average of 13.89%. That is roughly 38.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Taro Pharmaceutical Industries's current 8.56% should be judged against Healthcare norms (sector average: 13.89%) and against TARO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 8.56%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for Taro Pharmaceutical Industries, and consider following TARO for alerts when major investors trade the stock.